Contribution of in vivo models of thrombosis to the discovery and development of novel antithrombotic agents

This publication has 118 references indexed in Scilit:

• Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial
  The Lancet, 1999
• Administration of Abciximab During Percutaneous Coronary Intervention Reduces Both Ex Vivo Platelet Thrombus Formation and Fibrin Deposition
  Arteriosclerosis, Thrombosis, and Vascular Biology, 1998
• Selective Inhibition of Factor Xa Is More Efficient Than Factor VIIa–Tissue Factor Complex Blockade at Facilitating Coronary Thrombolysis in the Canine Model
  JACC, 1996
• Low-Molecular-Weight Heparin (Fragmin) and Thrombin Active-Site Inhibitor (Argatroban) Compared in Experimental Arterial and Venous Thrombosis and Bleeding Time
  Journal of Cardiovascular Pharmacology, 1996
• Effect of Selective Factor Xa Inhibition on Arterial Thrombus Formation Triggered by Tissue Factor/Factor VIIa or Collagen in an Ex Vivo Model of Shear-Dependent Human Thrombogenesis
  Arteriosclerosis, Thrombosis, and Vascular Biology, 1995
• Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition
  Cardiovascular Research, 1994
• Lack of usefulness of prolonged bleeding times in predicting hemorrhagic events in patients receiving the 7E3 glycoprotein IIb/IIIa platelet antibody
  The American Journal of Cardiology, 1993
• Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris
  JACC, 1993
• Ischemic stroke and intracranial hemorrhage following thrombolytic therapy for acute myocardial infarction: A risk-benefit analysis
  The American Journal of Cardiology, 1992
• Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial.
  Circulation, 1984